Major depressive disorder

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Monday, February 12, 2024
Ophthalmology, Polygala, NET, EOP, FDA, Attention deficit hyperactivity disorder, Patent, Treatment, Phase II, Norepinephrine transporter, Neurology, Norepinephrine, European, CNS, Major depressive disorder, Map, ADHD, MDD, Pharmaceutical industry

2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).

Key Points: 
  • 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.
  • The patent application was submitted to the Australian Patent and Trademark Office under "Polygala Extract for the Treatment of Major Depressive Disorder."
  • The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder.

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego

Retrieved on: 
Monday, February 12, 2024
Neuroscience, Neuropsychiatry, BIO, Conference, CKD, Therapy, CNS, Patient, Major depressive disorder, MDD, Partnership, Pharmaceutical industry

NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences.

Key Points: 
  • NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences.
  • “It is an honor to return to my home country, the Netherlands, a pioneer in neuroscience, to present Healis Therapeutics, the leading biotech company in neuromodulation,” said Sebastian De Beurs, Co-Founder of Healis.
  • Healis will also be present at the BIO CEO & Investor Conference held in New York, NY on February 26-27, and at the Global Life Science Partnering & Investor Conference in San Diego, CA on February 28-29.
  • “We are excited to continue our dialogue with the world’s leading neuroscience investors and stakeholders” said Dr. Eric Finzi, who Co-Founded Healis Therapeutics.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Unchained Wellness Clinic Paves the Way for Revolutionary Mental Health Care in Gilbert, Arizona

Retrieved on: 
Thursday, February 1, 2024
Theta, PTSD, Anxiety, Multimedia, Inflammation, Transcranial magnetic stimulation, Medication, Life, Sobriety, Immune system, Habit, FDA, Wellness, ADHD, OCD, Law enforcement, Unchained, TMS, Depression, Social media, Hyperbaric medicine, Brain, Privacy, Hope, ADD, Naturopathy, Major depressive disorder, Veteran, Nursing

GILBERT, Ariz., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Unchained Wellness Clinic, a beacon of hope for individuals grappling with mental health challenges, proudly announces its grand opening scheduled for February 2024. Situated in Gilbert, Arizona, this innovative wellness center takes a groundbreaking approach to treat conditions such as depression, anxiety, OCD, PTSD, ADD, ADHD, and addictions without solely relying on medications. Unchained Wellness specializes in identifying the root causes of behavioral health issues and offers a diverse range of services, providing comprehensive care through traditional medications, integrative health, and cutting-edge modalities.

Key Points: 
  • GILBERT, Ariz., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Unchained Wellness Clinic, a beacon of hope for individuals grappling with mental health challenges, proudly announces its grand opening scheduled for February 2024.
  • Unchained Wellness specializes in identifying the root causes of behavioral health issues and offers a diverse range of services, providing comprehensive care through traditional medications, integrative health, and cutting-edge modalities.
  • Unchained wellness gave me a huge jump forward in the healing process that I have never gotten any other way."
  • Unchained Wellness strategically targets towns in Arizona, with a primary focus on Gilbert, Mesa, Chandler, Scottsdale, Tempe, and Queen Creek.

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Retrieved on: 
Monday, January 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Alternative Medicine, General Health, Health, Other Health, NEO, Plasma, Data, Major depressive disorder, PD, GAD, Part, Patient, Safety, DMT, Inc., Pharmaceutical industry

CYB004 and SPL028 are proprietary deuterated DMT molecules within the Company’s DMT program in development for the treatment of generalized anxiety disorder.

Key Points: 
  • CYB004 and SPL028 are proprietary deuterated DMT molecules within the Company’s DMT program in development for the treatment of generalized anxiety disorder.
  • Results from the Phase 1 studies in the CYB004 and SPL028 programs demonstrated PK and PD profiles with the potential to bridge data across these molecules, and the PK profiles for both molecules demonstrated concentrations in the effective range.
  • “The positive data from our Phase 1 studies of CYB004 and SPL028 are highly encouraging with the combined data from these studies enabling us to prioritize our 2024 development plan for our deuterated DMT program.
  • Deuteration of DMT, as with CYB004, resulted in stronger psychedelic effects at lower plasma concentrations, compared with native DMT.

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Retrieved on: 
Thursday, January 4, 2024
Atypical depression, Treatment, Sale, Psilocybin, Depression, Major depressive disorder, Mental health, Webcast, MDD, Patient, TRD, Therapy, Pharmacology, Pharmaceutical industry

This strategic investment and collaboration aims to accelerate the development of Beckley Psytech’s two clinical-stage, patent-protected, short-duration psychedelic candidates, BPL-003 and ELE-101, by adding them to atai’s mental health innovation platform.

Key Points: 
  • This strategic investment and collaboration aims to accelerate the development of Beckley Psytech’s two clinical-stage, patent-protected, short-duration psychedelic candidates, BPL-003 and ELE-101, by adding them to atai’s mental health innovation platform.
  • “This transaction underscores our conviction in the potential of psychedelics as groundbreaking treatments for people living with mental health disorders.
  • atai Life Sciences will host a conference call and live webcast on Thursday January 4, 2024 at 8:00 a.m.
  • The conference call can be accessed on the Investors section of atai Life Sciences’ website under News, Events & Presentations, via the following link: https://ir.atai.life/news-events/events.

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

Retrieved on: 
Tuesday, January 2, 2024
Partnership, Post-traumatic stress disorder, Mental health, Depression, Research, WHO, Major depressive disorder, Therapy, PTSD, Bangladesh Technical Education Board, World Health Organization, MDD, Patient, Veterans' affairs, CKD

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.
  • CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.
  • Healis Therapeutics intends to develop CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
  • “Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans” said Sebastian De Beurs, Co-Founder of Healis.

Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder

Retrieved on: 
Monday, December 4, 2023
Research, Mental Health, Neurology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Major depressive disorder, Brain, Depression, Safety, Grammatical mood, Clinical trial, Data, Patient, Medicine, American College, Neuroscience, MADRS, EEG, Biomarker, Alto, MDD, Medical device, Medical imaging

Alto Neuroscience, Inc. today announced positive results from its Phase 2a study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).

Key Points: 
  • Alto Neuroscience, Inc. today announced positive results from its Phase 2a study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).
  • The company has initiated a Phase 2b study evaluating ALTO-300 in 200 patients with MDD, which is expected to read out in the first half of 2025.
  • Topline results from the ALTO-300 Phase 2a study include:
    A reproducible, readily scalable, and easily administered machine learning-derived EEG biomarker was identified.
  • Alto is leveraging this biomarker and prospective patient identification with EEG in its ongoing Phase 2b trial of ALTO-300.

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Retrieved on: 
Thursday, November 9, 2023
Health policy, Policy, OH, MDD, TMS, STIM, Blue Cross Blue Shield Association, HI, Neuronetics, Major depressive disorder, DSM-IV codes, Psychotherapy, Criterion, OR, Quality of life, Marketing, Aetna, Transcranial magnetic stimulation, BCBS, SSM Health, CO, Patient, Regenerative Medicine Advanced Therapy, Pharmaceutical industry, Health insurance, Ferdinand Magellan, UnitedHealth Group, MD

Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.

Key Points: 
  • Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.
  • The policy updates from BCBS Kansas City and Dean Health Plan are effective immediately, with the Magellan update going into effect on November 18, 2023.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, November 8, 2023
Other Health, Pharmaceutical, Optical, Oncology, General Health, Mental Health, Medical Devices, Neurology, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Real-World Evidence, NEI, MDD, Congress, Medication, RWE, RCT, Bradley, Poster, Major depressive disorder, Depression, Patient, Randomized controlled trial, Grammatical mood, DDI, Medical device

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a single-site, open-label study demonstrating the consistent impact of IDgenetix® on medication response and remission rates in patients with major depressive disorder (MDD).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a single-site, open-label study demonstrating the consistent impact of IDgenetix® on medication response and remission rates in patients with major depressive disorder (MDD).
  • Compared to patients in the unguided group, response rates for the IDgenetix-guided participants improved by 37% in the RCT vs. 32% in the RWE.
  • Overall, comparing the clinical outcome results from the RCT with RWE demonstrated the consistent impact of IDgenetix on patient response and remission rates.
  • This study provides evidence-based research that supports the clinical use of IDgenetix to guide medication management in patients with MDD.